• صفحه اصلی
  • مقایسه تأثیر ویتامین E و بره موم (پروپولیس) بر اینترلوکین-5 و بیان ژن STAT1 در موش های ویستار مبتلا به کبد چرب غیرالکلی

اشتراک گذاری

آدرس مقاله


کد مقاله : ASCIJ-2203-1371 بازدید : 271 صفحه: 21 - 31

10.22034/ascij.2022.1953654.1371

نوع مقاله: پژوهشی

مقایسه تأثیر ویتامین E و بره موم (پروپولیس) بر اینترلوکین-5 و بیان ژن STAT1 در موش های ویستار مبتلا به کبد چرب غیرالکلی

محورهای موضوعی : فصلنامه زیست شناسی جانوری

سعیده بارفروش 1 , مریم بنانج 2 , رامین حاجی خانی 3 , هنگامه علی بیک 4

1 - گروه زیست شناسی، واحد تهران شمال، دانشگاه آزاد اسلامی، تهران، ایران
2 - گروه زیست شناسی، واحد تهران شمال، دانشگاه آزاد اسلامی، تهران، ایران
3 - گروه زیست شناسی، واحد تهران شمال، دانشگاه آزاد اسلامی، تهران، ایران
4 - گروه زیست شناسی، واحد تهران شمال، دانشگاه آزاد اسلامی، تهران، ایران

تاریخ دریافت : 1400/12/11 تاریخ پذیرش : 1401/07/23 تاریخ انتشار : 1401/12/01

کلید واژه: ویتامینE, بره موم, کبد چرب غیرالکلی, ژن STAT1, اینترلوکین-5,

چکیده مقاله :

بیماری کبد چرب غیرالکلی (NAFLD) یک نگرانی فزاینده برای سلامتی در سراسر جهان است. متأسفانه دانشمندان موفق به یافتن روش درمانی مناسب برای این بیماری نشده اند و نیاز به تحقیقات بیشتری دارد. مطالعات نشان داده اند که درمان با آنتی اکسیدان ها در این بیماری مؤثر است. در این مطالعه، اثر دو آنتی اکسیدان مختلف بر NAFLD القا شده به رت های ویستار نر ارزیابی شد. این مطالعه بر روی 32 سر رت نر ویستار با وزن 200 گرم انجام شد که بصورت تصادفی به چهار گروه هشت تایی تقسیم شدند. موش ها توسط امولوسیون پرچرب به میزان 2 میلی گرم بر کیلوگرم به مدت 40 روز با گاواژ تغذیه شدند. پس از ابتلا به کبدچرب، میزان اینترلوکین-5 (IL-5) سرمی اندازه گیری شد و همچنین با استفاده از Real-time PCR، میزان بیان ژن STAT1 تعیین گردید. یافته ها نشان داد که میزان IL-5سرمی در گروه بیمار بصورت معناداری نسبت به گروه کنترل افزایش داشت و تیمار گروه ها با ویتامین E و بره موم میزان اینترلوکین-5 را بصورت معناداری نسبت به گروه بیمار کاهش داد (05/0 > p). بعلاوه، بیشترین کاهش مربوط به گروه بره موم بود (05/0 > p). از طرفی دیگر، میزان بیان ژن STAT1 نیز در گروه مبتلا به کبدچرب بصورت معناداری نسبت به گروه کنترل افزایش دارد (05/0 > p)؛ درحالیکه، پس از تیمار با آنتی اکسیدان ها بیان این ژن کاهش یافت (05/0 > p). براساس نتایج بدست آمده، استفاده از بره موم و همچنین ویتامین E به عنوان آنتی اکسیدان های طبیعی با کاهش اینترلوکین التهابی و همچنین کاهش بیان ژن موثر در شکل گیری NAFLD، نقش درمانی امیدوارکننده ای در کبد چرب غیرالکلی دارند.

چکیده انگلیسی:

Nonalcoholic fatty liver disease (NAFLD) is a growing health concern worldwide. Unfortunately, scientists have not succeeded in finding a suitable treatment method for this disease, and more research is needed. Studies have shown that treatment with antioxidants is effective in this disease. In this study, the effect of two different antioxidants on NAFLD induced in male Wistar rats was evaluated. This study was conducted on 32 male Wistar rats weighing 200 grams, which were randomly divided into four groups of eight. Mice were fed by gavage with high-fat emulsion at the rate of 2 mg/kg for 40 days. After suffering from fatty liver, the level of interleukin-5 (IL-5) in the serum was measured and also the expression level of STAT1 gene was determined using real-time PCR. The results showed that the level of serum IL-5 in the patient group significantly increased compared to the control group, and the treatment groups with vitamin E and propolis, significantly decreased the level of interleukin-5 compared to the patient group (p < 0.05). In addition, the greatest decrease was related to the propolis group (p < 0.05). On the other hand, the level of STAT1 gene expression in the fatty liver group is significantly increased compared to the control group (p < 0.05); Whereas, after treatment with antioxidants, the expression of this gene decreased (p < 0.05). Based on the obtained results, the use of propolis and also vitamin E as natural antioxidants by reducing the inflammatory interleukin and also reducing the expression of genes effective in the formation of NAFLD, have a promising therapeutic role in non-alcoholic fatty liver disease.

منابع و مأخذ:

1.        Bai J., Wu L., Chen X., Wang L., Li Q., Zhang Y., Wu J., Cai G., Chen X. 2018. Suppressor of Cytokine Signaling-1/STAT1 Regulates Renal Inflammation in Mesangial Proliferative Glomerulonephritis Models. Frontiers in Immunology, 9:1982.

  1. Bellentani S., Scaglioni F., Marino M., Bedogni G. 2010. Epidemiology of non-alcoholic fatty liver disease. Digestive Diseases, 28(1):155-161.
    2.
  2. Chung M.Y., Yeung S.F., Park H.J., Volek J.S., Bruno R.S. 2010. Dietary α-and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. The Journal of Nutritional Biochemistry, 21(12):1200-1206.
    3.
  3. CotterG., Rinella M. 2020. Nonalcoholic Fatty Liver Disease: The State of the Disease. Gastroenterology, 158(7):1851-1864.
    4.
  4. Croker B.A., Kiu H., Nicholson S.E. 2008. SOCS regulation of the JAK/STAT signalling pathway. Seminars in Cell and Developmental Biology, Elsevier.
    5.
  5. Daleprane J.B., Abdalla D.S. 2013. Emerging roles of propolis: antioxidant, cardioprotective, and antiangiogenic actions. Evidence-based Complementary and Alternative Medicine, 2013:175135.
    6.
  6. El Hadi H., Vettor R., Rossato M. 2018. Congenital vitamin E deficiency. Handbook of Famine, Starvation, and Nutrient Deprivation; Preedy, VR, Patel, VB, Eds. 2018:1-18.
    7.
  7. Federico A., Dallio M., Masarone M., Gravina A.G., Di Sarno R., Tuccillo C. 2019 Evaluation of the effect derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients. Oxidative Medicine and Cellular Longevity, 2019: 8742075.
    8.
  8. Hadi H.E., Vettor R., Rossato M. 2018. Vitamin E as a treatment for nonalcoholic fatty liver disease: reality or myth? Antioxidants, 7(1):12.
    9.
  9. Haghighatfard A., Andalib S., Amini Faskhodi M., Sadeghi S., Ghaderi A.H., Moradkhani S. 2018. Gene expression study of mitochondrial complex I in schizophrenia and paranoid personality disorder. The World Journal of Biological Psychiatry, 19(sup3):S133-S146.
    10.
  10. Ji H.F., Sun Y., Shen L. 2014. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis. Nutrition, 30(9):986-991.
    11.
  11. Jin X.L, Wang K., Li Q.Q., Tian W.L., Xue X.F., Wu L.M. 2017. Antioxidant and anti-inflammatory effects of Chinese propolis during palmitic acid-induced lipotoxicity in cultured hepatocytes. Journal of Functional Foods, 34:216-223.
    12.
  12. Kismet K., Ozcan C., Kuru S., Celemli O.G., Celepli P., Senes M. 2017. Does propolis have any effect on non-alcoholic fatty liver disease? Biomedicine and Pharmacotherapy, 90:863-871.
    13.
  13. Lirussi F., Azzalini L., Orando S., Orlando R., Angelico F. 2007. Antioxidant supplements for non‐alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews, 2007(1): CD004996.

  14. Loguercio C., Andreone P., Brisc C., Brisc M.C., Bugianesi E., Chiaramonte M. 2012. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radical Biology and Medicine, 52(9):1658-1665.
    15.
  15. Mohamed E.H., Baiomy A.A., Ibrahim Z.S., Soliman M.M. 2016. Modulatory effects of levamisole and garlic oil on the immune response of Wistar rats: Biochemical, immunohistochemical, molecular and immunological study. Molecular Medicine Reports, 14(3):2755-2763.
    16.
  16. Mujica V., Orrego R., Pérez J., Romero P., Ovalle P., Zúñiga-Hernández J. 2017. The role of propolis in oxidative stress and lipid metabolism: a randomized controlled trial. Evidence-Based Complementary and Alternative Medicine, 2017:4272940.
    17.
  17. Murphy S.K., Yang H., Moylan C.A., Pang H., Dellinger A., Abdelmalek F. 2013. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology, 145(5):1076-1087.
    18.
  18. Musso G., Gambino R., Cassader M., Pagano G. 2010. A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology, 52(1):79-104.
    19.
  19. Nagashimada M., Ota T. 2019. Role of vitamin E in nonalcoholic fatty liver disease. Iubmb Life, 71(4):516-522.
    20.
  20. Nan Y.M., Wu W.J., Fu N., Liang B.L., Wang R.Q., Li L.X. 2009. Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scandinavian Journal of Gastroenterology, 44(9):1121-1131.
    21.
  21. Nobili V., Manco M., Devito R., Ciampalini P, Piemonte F., Marcellini M. 2006. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non‐alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 24(11‐12):1553-1561.
    22.
  22. Oliveira C.P., da Costa Gayotto L..C, Tatai C., Della Nina B.I., Lima S., Abdalla D.S., 2003. Vitamin C and vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutrition Journal, 2(1):1-5.
    23.
  23. Perdomo C.M., Frühbeck G., Escalada J. 2019. Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients, 11(3):677.
    24.
  24. Phung N, Farrell G, Robertson G, George J, editors. Vitamin E but not glutathione precursors inhibit hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology; 2001: WB Saunders Co Independence Square West Curtis Center, STE 300, Philadelphia.
    25.
  25. Podszun M.C., Alawad A.S., Lingala S., Morris N., Huang W.C.A., Yang S. 2020. Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox Biology, 37:101710.
    26.
  26. Phung N., Pera N., Farrell G., Leclercq I., Hou J.Y., George J. 2009. Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. International Journal of Molecular Medicine, 24(2):171-180.
    27.
  27. Ramachandran S., Singh M.K., Mobeen A., Chandra A., Joshi S. 2021. A Meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection. Computers in Biology and Medicine, 130:104219.
    28.
  28. RenningerL., Seymour R.E., Whiteley L.O., Sundberg J.P., HogenEsch H. 2010. Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis in SHARPIN-deficient mice. Experimental Dermatology, 19(3):252-258.

  29. Romeo S., Sanyal A., Valenti L. 2020. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metabolism, 31(1):35-45.
    30.
  30. Sato K., Gosho M., Yamamoto T., Kobayashi Y., Ishii N., Ohashi T. 2015. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition, 31(7-8):923-930.
    31.
  31. Sepidarkish M., Akbari-Fakhrabadi M., Daneshzad E., Yavari M., Rezaeinejad M., Morvaridzadeh M. 2020. Effect of omega-3 fatty acid plus vitamin E Co-Supplementation on oxidative stress parameters: A systematic review and meta-analysis. Clinical Nutrition, 39(4):1019-1025.
    32.
  32. Shen X.H., Tang Q.Y., Huang J., Cai W. 2010. Vitamin E regulates adipocytokine expression in a rat model of dietary-induced obesity. Experimental Biology and Medicine, 235(1):47-51.
    33.
  33. Socha P., Horvath A., Vajro P., Dziechciarz P., Dhawan A., Szajewska H. 2009. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. Journal of Pediatric Gastroenterology and Nutrition, 48(5):587-596.
    34.
  34. Soden J.S., Devereaux M.W., Haas J.E., Gumpricht E., Dahl R., Gralla J. 2007. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatology, 46(2):485-495.
    35.
  35. Soleimani D., Rezaie M., Rajabzadeh F., Gholizadeh Navashenaq J., Abbaspour M., Miryan M. 2021. Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real‐time two‐dimensional shear wave elastography: A randomized clinical trial. Phytotherapy Research, 35(3):1669-1679.
    36.
  36. Studio del Fegato, Società Italiana di Diabetologia, Società Italiana dell’Obesità  Members of the guidelines panel. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutrition, Metabolism and Cardiovascular Diseases, 32(1):1-16.
    37.
  37. Türkez H., Yousef M.I., Geyikoglu F. 2010. Propolis prevents aluminium-induced genetic and hepatic damages in rat liver. Food and Chemical Toxicology, 48(10):2741-2746.
    38.
  38. Willebrords J., Pereira I.V.A, Maes M., Yanguas S.C., Colle I., Van Den Bossche B. 2015. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Progress in Lipid Research, 59:106-25.
    39.
  39. Yang J., Fernández-Galilea M., Martínez-Fernández L., González-Muniesa P., Pérez-Chávez A., Martínez J.A. 2019. Oxidative stress and non-alcoholic fatty liver disease: effects of omega-3 fatty acid supplementation. Nutrients, 11(4):872.
    40.
  40. Zou Y., Li J., Lu C., Wang J., Ge J., Huang Y., 2006. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sciences, 79(11):1100-1107.
    41.

 

_||_

مقالات مرتبط

حقوق این وب‌سایت متعلق به سامانه مدیریت نشریات دانشگاه آزاد اسلامی است.
حق نشر © 1403-1400

صفحه اصلی| عضویت/ ورود| درباره سند| تماس با ما|
[English] [العربية] [en] [ar]